Related Experiment Videos

The current management of pancreatic neuroendocrine tumors

Trevor A Ellison1, Barish H Edil

  • 1Department of Surgery, The Johns Hopkins Hospital, 1550 Orleans Street, CRB II, Room 506, Baltimore, MD 21287, USA.

Advances in Surgery
|August 10, 2012
PubMed

Insights

Pancreatic neuroendocrine tumors (PanNETs) are rare but have a better prognosis than pancreatic cancer. Research is exploring new targeted therapies and clinical trials to improve PanNET patient management.

Area of Science:

  • Oncology
  • Gastroenterology
  • Endocrinology

Background:

  • Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms.
  • PanNETs exhibit heterogeneity and a generally better prognosis than pancreatic adenocarcinoma.
  • Surgery remains the only curative treatment for PanNETs.

Purpose of the Study:

  • To review the current understanding and management of PanNETs.
  • To highlight advancements in adjuvant and targeted therapies for PanNETs.
  • To emphasize the growing interest and ongoing research in PanNETs.

Main Methods:

  • Literature review of existing studies on PanNETs.
  • Analysis of current treatment strategies, including surgery and adjuvant therapies.
  • Overview of recently approved targeted therapies and ongoing clinical trials.

Main Results:

  • PanNETs represent a distinct group of pancreatic tumors with unique characteristics.
  • Adjuvant therapies, including novel targeted treatments, are increasingly explored for PanNETs.
  • Significant interest is driving new clinical trials and natural history studies.

Conclusions:

  • Despite rarity, PanNETs warrant dedicated research due to their distinct clinical behavior.
  • Advancements in targeted therapies offer new hope for PanNET management.
  • Further research, including clinical trials, is crucial for optimizing patient outcomes.